Scarica l'app Stockscreener
6.07
9.57%
0.53
Pre-mercato:
6.07
Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie
Risks Report: Can Sagimet Biosciences Inc deliver alpha2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn
SGMT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Sagimet Biosciences Presents Research at Metabolic Health Summit - National Today
Sagimet Biosciences Inc. (hereinafter referred to as "Sagimet") announced that its latest research progress will be presented at the "Fueling MASH: Metabolic Drivers and Inflammatory Interactions" Keystone Symposium through poster and oral presentations. - Bitget
Sagimet Biosciences to Present Phase 2b FASCINATE 2 Trial Data for Denifanstat at Keystone Symposium on Metabolic Drivers and Inflammatory Crosstalk - Quiver Quantitative
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Weekly Voice
If You Invested $1,000 in Sagimet Biosciences Inc. (SGMT) - Stock Titan
Sagimet Biosciences Inc (0O2.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Barclays Maintains Sagimet Biosciences(SGMT.US) With Hold Rating, Maintains Target Price $8 - Moomoo
SGMT SEC FilingsSagimet Biosciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $26 - Moomoo
ETF Watch: What is Sagimet Biosciences Incs TAM Total Addressable MarketM&A Rumor & Risk Managed Investment Signals - baoquankhu1.vn
SGMT Stock Price, Quote & Chart | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Rodman & Renshaw - MarketBeat
Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results - Insider Monkey
Top 10 Stocks Under $5 That Could Triple - Insider Monkey
Aug Rallies: How does Sagimet Biosciences Inc score in quality rankingsRisk Management & Consistent Growth Stock Picks - baoquankhu1.vn
Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study - MSN
Sagimet rises after denifanstat succeeds in late stage trial - MSN
Total debt per share of Sagimet Biosciences Inc. Class A – DUS:0O2 - TradingView
EBIT per share of Sagimet Biosciences Inc. Class A – DUS:0O2 - TradingView
HC Wainwright Has Negative Outlook for SGMT FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Upgraded to "Hold" at Wall Street Zen - marketbeat.com
Q1 Earnings Forecast for SGMT Issued By HC Wainwright - MarketBeat
Citizens reiterates Sagimet Biosciences stock rating on MASH progress - Investing.com UK
Citizens reiterates Sagimet Biosciences stock rating on MASH progress By Investing.com - Investing.com Nigeria
Sagimet: Advancing FASN Inhibitor Pipeline and Solid Cash Position Support Buy Rating and $26 Target - TipRanks
Sagimet: Underappreciated, De-Risked Pipeline with Near-Term Milestones Supports Buy Rating - TipRanks
Sagimet Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sagimet Biosciences Reports 2025 Financial Results, Advances MASH and Acne Clinical Programs with Denifanstat and Resmetirom Combination 14 - Minichart
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oppenheimer reiterates Sagimet stock rating on MASH trial progress By Investing.com - in.investing.com
Oppenheimer reiterates Sagimet stock rating on MASH trial progress - Investing.com
Sagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC Wainwright - MarketBeat
Sagimet: Undervalued MASH and Acne Pipeline with Best-in-Class Combination Potential Supports Buy Rating - TipRanks
Sagimet Biosciences Advances FASN Inhibitor Pipeline with Positive Phase 3 Results for Denifanstat in Acne and MASH Clinical Trials - Minichart
Sagimet Biosciences (NASDAQ:SGMT) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress - TipRanks
MASH and acne trial gains highlight Sagimet (NASDAQ: SGMT) 2025 update - Stock Titan
Sagimet Biosciences Q4 net loss narrows as R&D expenses fall - TradingView
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - The Manila Times
SGMT: Positive clinical progress in MASH and acne, with $113.1M cash and $51.0M net loss in 2025 - TradingView
Sagimet 10-K: Net Loss $51.0M, EPS $(1.58) - TradingView
Acne drug filing in China, new liver trial planned by Sagimet - Stock Titan
Sagimet Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday - MarketBeat
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):